Role of percutaneous left ventricular assist devices in preventing cerebral ischemia

Percutaneous left ventricular assist devices improve hemodynamics in acute heart failure. The devices can be deployed rapidly and with a low risk of complications, and may thereby offer potential advantages compared with surgical assist systems in the critically ill. Cerebral hypoperfusion with cerebral injury is a major challenge in acutely ill cardiac patients, especially when cardio–pulmonary resuscitation is performed. There is no indication that catheter-based left ventricular assist devices confer more cerebrovascular complications than current percutaneous angiographic and interventional procedures. Recent data suggest that microcirculation in the head may be improved during percutaneous assist device support in cardiogenic shock. Specific assessment of the effect of a percutaneous device during cardiac arrest and impaired cerebral circulation has been performed in newly published experimental protocols. The available data indicate that a percutaneous intracardiac impeller device may be able to sustain cerebral perfusion during cardiac arrest. Assessment of metabolic markers in the brain, using intracerebral microdialysis during ventricular fibrillation, indicates ischemic brain injury may be avoided during cardiac arrest lasting 20–40 min without simultaneous chest compressions. The use of percutaneous left ventricular assist devices may have the potential to prevent ischemic brain damage and improve clinical outcomes for patients with cardiac collapse and impaired cerebral circulation. Randomized clinical studies are necessary to validate these new treatment concepts.

KEYWORDS: cardiac arrest cardiacogenic shock cerebral ischemia metabolism percutaneous ventricular assist devices resuscitation revascularization tissue perfusion

Left ventricular assist devices (LVADs) provide systemic blood delivery and myocardial unloading in severe heart failure, including the acute setting [1–7]. Recently developed percutaneous ventricular assist devices (PVADs) have the advantage of rapid deployment. Safety and feasibility for short-term use have been established, and PVADs have been assessed in acute myocardial infarction, cardiogenic shock, severe heart failure, in high-risk coronary recirculation, and as a bridge to permanent treatment in decompensated heart failure [8–15]. PVADs unload the heart and improve vital organ perfusion, and recent data indicate the ability of such a device to maintain cerebral and myocardial perfusion during experimental cardiac arrest [16,17].

Contrary to the substantial advances seen in the treatment of chronic heart failure, acute severe heart failure with circulatory insufficiency still has a poor prognosis [18–21]. In cardiogenic shock, tissue hypoperfusion is regularly present, and vital organ dysfunction with tissue damage is frequent [22–24]. In resuscitated patients, cerebral injury is the major limiting factor for clinical outcomes in survivors [25–27].

In this overview, we aim to focus on the potential of PVAD technology to provide protection against acute ischemic cerebral injury in acute hemodynamic collapse.

**Current treatment**

Treatment strategies for reducing cerebral and myocardial ischemic injury (cardiocerebral resuscitation) make use of urgent hypothermia and coronary revascularization in addition to conventional cardiopulmonary resuscitation (CPR) and have improved clinical outcomes in recent investigations (Figure 1) [28].

Acute hemodynamic interventions in these critically ill patients, including urgent cardiopulmonary bypass, sophisticated resuscitation algorithms and medical therapy, have been studied but have not resulted in better outcomes in clinical practice [29–33].

Moreover, vasopressors and inotropes may have detrimental circulatory and metabolic effects despite the intuitive benefit of increased arterial pressures. Experimentally, both cerebral and coronary perfusion have been shown to be impaired with the use of vasopressor therapy during cardiac arrest [32–34]. Adverse effects...
have also been indicated on clinical outcomes in resuscitation [35]. Intra-aortic balloon pump (IABP) therapy has been extensively used in cardiogenic shock, but has not been demonstrated to improve mortality. Furthermore, IABP use has been associated with an increased risk of stroke in ST elevation myocardial infarction in a recent meta-analysis [36].

Mechanical cardiac assist devices are established treatment choices in chronic heart failure and reduce left ventricular workload and oxygen consumption with possible beneficial effects on myocardial metabolism and function [37,38]. In acute cardiac disease with very low cardiac output state, it has been suggested that emergent use of heart assist therapy may unload the left ventricle and may also augment perfusion of the vital organs [39–41]. In particular, brain damage due to cerebral hypoperfusion represents a major limitation for clinical outcomes for patients surviving acute hemodynamic collapse [42,43] and LVAD support may increase cerebral blood flow (CBF) [44,45].

Surgical LVADs have been implanted successfully in acute decompensated heart failure and may be useful as a bridge to permanent treatment or recovery for selected patients after initial stabilization [46,47]. Available cardiac assist systems also include cardiopulmonary bypass (CPB) and extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS), which have the potential to sustain circulation during cardiac standstill [48–51]. Reports on the use of ECMO, ECLS and CPB in cardiogenic shock and cardiac arrest have shown the feasibility of such interventions, but the potential to improve survival has not been established in these settings [52–57]. Acute implantation has a high risk of complications and requires highly specialized personnel and facilities, thus emergency surgical LVAD support is not routinely available in the treatment of acute heart failure and technical limitations may represent a substantial drawback in a critical setting.

### Percutaneous left ventricular assist devices

Ideally, intervention in acute cardiac collapse should sustain sufficient cerebral perfusion to avoid ischemic injury in order to allow for treatment of the underlying disease. Moreover, the intervention should be readily available, easy to establish and any risk of complications should be minimized. Percutaneous assist devices have the potential to meet these requirements.

There are several benefits of percutaneous devices over surgical devices. The generally smaller size and reduced vascular trauma with percutaneous devices can reduce the risk of bleeding and vascular compromise during implantation and use. By permitting rapid hemodynamic support with less complicated implantation procedures, a percutaneous approach seems especially useful for the acute treatment of patients with hemodynamic collapse. Systemic blood delivery may be sufficient to prevent short-term tissue ischemia [58–61]. Depending on the ability to maintain vital organ blood delivery over time, such devices may also be of use during surgical cardioplegia and cardiac arrest.

The two systems in clinical use are the TandemHeart® and the Impella® LP 2.5 (Figure 2). Both of these devices fulfill the criteria for a true LVAD, being able to reduce myocardial workload, and to transport oxygenated blood into the systemic circulation [62]. Hemodynamic and experimental findings indicate both systems may be effective, and clinical data have suggested low complication rates when used for an extended time-period [15,63–66]. For both the devices, bleeding and limb ischemia represent the majority of reported rare but severe complications; both have been studied in unstable and stable patients, and indications for use in clinical practice include high-risk percutaneous coronary intervention and cardiogenic shock [8–15].
The TandemHeart device is a catheter-based left atrial-to-femoral bypass system delivering up to 10 l of blood per minute. Implantation requires large diameter catheters (21 F), and trans-septal–septal puncture. Deployment time is approximately 30 min and complication rates have been reported to be low during clinical use [67]. The Impella LP 2.5 device is a miniature impeller pump that is placed retrogradely into the left ventricle via a 13 F femoral artery sheath with a capacity to pump 2.5 l of blood per minute into the ascending aorta. Placement into the left ventricle may be rapidly performed and the risk of complications has been found to be low [67].

In the presence of femoral or iliac artery disease, access may be obtained with stenting of stenotic vessels prior to implantation of the PVAD. In uncomplicated cases, the Impella LP 2.5 may be deployed within a few minutes, which may be of clinical importance in the treatment of acutely decompensated patients. Transient hemolysis has been reported for the Impella device. This does not regularly represent a clinical problem and measurement of free hemoglobin in serum will reliably differentiate between hemolysis and bleeding if anemia or clinical hematuria is present. Furthermore, potential aortic regurgitation represents a theoretical limitation with the trans-valvular device, but hemodynamically significant regurgitation has not been found to be an issue with regular use in patients with intrinsic heart rhythm [8,65].

The TandemHeart device requires a more complicated deployment procedure but has a higher delivery than the Impella LP 2.5. Although both devices deliver a substantially higher output than can be achieved by IABP devices, no clinical benefit has been demonstrated with PVAD compared with IABPs thus far [8,9], and despite intuitively beneficial potential, no PVAD has so far been able to demonstrate clinically beneficial outcomes during temporary use in critically ill patients [68].

The potential of the Impella LP 2.5 for improving blood flow to the head in awake subjects has been indicated [42]. However, the clinical role of PVADs in prevention of cerebral injury is likely to be most relevant for unconscious patients with severely compromised CBF. During cardiac standstill and profound hypotension, the potential for cerebral injury is obvious, and the settings of resuscitated hemodynamic collapse and cardiac arrest represent clinical situations where percutaneous cardiac assist systems may be of particular use. The Impella LP 2.5 has its inlet and outlet proximal to the carotid arteries, whereas only the inlet of the TandemHeart device is situated in the pre-cerebral arterial circulation with the outlet in the femoral artery (Figure 2). The outlet of the Impella device in the ascending aorta can allow for preferential flow to the cerebral and myocardial vessels [16,17,61,69]. Thus, the design of the Impella device could theoretically represent an advantage compared with a left atrial-to-femoral artery bypass system, although the TandemHeart device has a higher maximum output.
According to currently available data, no cerebral embolic complications have been reported with either of the two devices. However, only limited patient data have been published and specific assessment of cerebral injury has, to our knowledge, not been assessed during clinical PVAD support.

**Role of percutaneous left ventricular assist devices in preventing cerebral injury**

A benefit of PVADs in preventing cerebral injury is unlikely to be found in awake patients where cerebral circulation is adequate to maintain consciousness. Accordingly, in most conscious cardiogenic shock patients, cerebral circulation may be sufficient to avoid short-term ischemic brain damage without additional LVAD therapy.

In cardiac arrest, prognosis remains poor, and even with the immediate start of chest compressions, and urgent percutaneous coronary revascularization and cooling, cerebral injury is still a major problem in patients surviving the acute phase [70]. Thus, in patients with cardiac arrest and pulseless electrical activity requiring resuscitation, PVAD support may have the potential to significantly improve the delivery of oxygenated blood to the brain.

The delivery of oxygenated blood to the arterial circulation depends on adequate filling of the left heart from the pulmonary circulation. Measures that improve venous return can augment the available left-side blood volumes [71]. Intravenous fluid loading may be useful for this purpose [14,16,72]. Furthermore, abdominal compression devices can increase total peripheral resistance and vital organ perfusion pressures without the potential detrimental effect of medical vasopressor substances in this setting [73,74].

The use of PVAD therapy in cardiac arrest patients may be relevant as an adjunct to established resuscitation during concomitant chest compressions in the hyperacute setting, with a possible synergistic effect on vital organ blood delivery.

---

**Figure 3. Hemodynamics in cardiac arrest with percutaneous ventricular assist device support.** Experimental data with the Impella® LP 2.5. Subjects with sustained vital organ perfusion during percutaneous ventricular assist device support indicated in continuous lines, subjects without vital organ perfusion in dotted lines. Individuals in thin lines, means in fat lines. Time (min): time after start of ventricular fibrillation. Device was started directly after induction of cardiac arrest and run on maximal attainable output level. Reprinted with permission from [17].
Further benefits of PVAD therapy may be possible with a device able to obviate the need for chest compressions and vasopressor during ventricular fibrillation (VF), which could allow for more optimal coronary revascularization and medical stabilization of the patient. In order to achieve this, blood delivery from the device should be able to prevent acute cerebral injury and the hemodynamic and clinical effects of the device should not be inferior to established methods for cardiopulmonary resuscitation.

**Impella LP 2.5 in cardiac arrest**

To our knowledge, the Impella LP 2.5 is the only percutaneous LVAD that has been studied during cardiac arrest. Experimental data from pigs have demonstrated the ability of this device to maintain cerebral and myocardial perfusion for a limited period of VF, and results were improved with intravenous fluid loading [16].

Using the LP 2.5 together with fluid loading, CBF by microspheres could be consistently maintained above 60% of baseline values for a limited period and flow levels above 40% were sustained up to 45 min after onset of VF (Figure 3) [17].

During VF, cerebral ischemia was assessed with cerebral microdialysis. Measurements of metabolic markers of hypoxia and injury in the brain indicated that cerebral injury was avoided for 20 to 40 min of cardiac arrest (Figure 4) [17]. In this study, brain injury and cerebral perfusion were reliably identified by end-tidal CO₂ monitoring via the ventilator, allowing for the direct and continuous assessment of cerebral and systemic hemodynamics in a clinical situation with PVAD-assisted cardiac arrest [17]. Moreover, data were favorable when compared with conventional resuscitation with chest compressions and vasopressor therapy (Figure 5) [75].
In addition, in a recent experimental study in a porcine model, cerebral perfusion, hemodynamics, and rates of successful defibrillation were found to be comparable to optimal manual resuscitation with open chest cardiac massage, and no added benefit was found with the larger Impella LP.

Although initial experimental findings suggest that percutaneous LVAD support sustains vital organ perfusion during cardiac arrest, previous studies have indicated only a limited clinical effect of LVAD support, despite initially promising hemodynamic data. Current experimental data from percutaneous LVAD support during VF should obviously be interpreted with caution based on these previous experiences.

In clinical use, the larger Impella LP 5.0, of similar design with maximum output of 5 l per minute, is often preferred to the smaller LP 2.5 owing to its higher delivery and increased mechanical stability. However, the LP 5.0 is more bulky and requires surgical cut-down for arterial access, thus implantation can be somewhat more complicated than for the true percutaneous version. Once inserted, the larger device can achieve higher systemic blood delivery and could have the potential to improve hemodynamics compared with the LP 2.5. However, the device requires sufficient filling from the right side in order to achieve its output potential and efficacy may be limited by poor filling of the left ventricle. Experimental data indicate this may be a particular issue during VF where sufficient circulatory blood volumes cannot be obtained.

**Cerebral injury during circulatory support**

Cerebral hypoperfusion may be present during LVAD support, but severe neurological impairment is not common during long-term use in stabilized patients.

During cardiopulmonary bypass, CBF and cerebral perfusion pressure (CPP) are related to device output. Furthermore, blood oxygenation, hemoglobin levels, arterial microembolezation and anesthetic use have been demonstrated to affect the risk of cerebral injury.

Vasopressor therapy, inotropes and blood transfusions may be useful in preventing cerebral ischemia during controlled cardioplegia and in heart failure, but may be counterproductive in the case of treatment for acute circulatory collapse. Intra-arterial device therapy can theoretically be complicated by the introduction of air and thrombi, which may embolize into the cerebral circulation and contribute to brain injury. The devices may further cause blood clot activation and thrombus dislodgement owing to blood flow turbulence from the pumps. In addition, mechanical fragmentation...
Role of percutaneous left ventricular assist devices in preventing cerebral ischemia

Various other tools for monitoring of cerebral circulation are available in the acute clinical setting. CBF can be estimated at the bedside with transcranial Doppler flow measurements [100,101]. CBF values of 20–40% of normal baseline values have been suggested to be sufficient for prevention of acute cerebral injury [102,103]. CPP can be monitored using intracranial pressure transducers and arterial pressures to guide clinical treatment, although the minimal CPP values indicative of sustained cerebral perfusion have not been definitively resolved [104–106].

End-tidal CO₂ values from the ventilator have been demonstrated to be associated with CBF and outcomes after cardiac arrest. In patients where intrinsic cardiac function is insufficient to sustain circulation, end-tidal CO₂ values can be used for continuous assessment of the effect of hemodynamic support and of prognosis [107,108]. Generally, higher values are associated with near-normal systemic and cerebral circulation, whereas very low values can be used to predict death in prolonged resuscitation [109–111]. Similar correlations have been found in experimental studies of percutaneous LVAD support during VF [17].

Assessment of cerebral injury

Clinical data of cerebral damage during PVAD support have not been reported. Generally, examination of cerebral perfusion and metabolism can involve complicated and invasive procedures and may in some cases be in conflict with guidelines for accepted intervention. The experimental setting allows for controlled hemodynamic intervention, and experimental models make feasible more sophisticated monitoring of cerebral circulation, metabolism and injury. Animal models include the possibility for direct intracardiac and intravascular monitoring and sampling, and also tissue flow measured with labeled microsphere injections, which is considered a gold standard approach for the assessment of tissue perfusion. Analysis requires harvesting of tissue for photometroscopic analysis, which complicates the use of this method in human subjects [88,89].

The newly developed cerebral microdialysis represents a method for the direct assessment of cerebral metabolism and redox state and is related to cerebral perfusion and to neurological injury [90–92]. With this technique, a miniature intracerebral dialysis catheter implanted via a cranial burr hole allows for continuous sampling of intracerebral molecules (Figure 6). Intracerebral dialysate can be analyzed for metabolic markers during clinical and experimental cerebral ischemia or injury. The method has been validated clinically and experimentally and is established in clinical use for monitoring of patients with cerebral injury [93–97]. Available data include reports from cerebral trauma, intracranial hemorrhage, cardioplegia and resuscitated cardiac arrest [17,98,99]. During cerebral hypoperfusion, markers of ischemia or injury can be sampled and analyzed continuously, and changes in the metabolic status of the cerebral cortex can be detected with little delay and followed over time. It is likely that this technique will be useful in future studies of cerebral status in hemodynamically compromised patients.

Figure 6. Microdialysis principle. A microdialysis probe of concentric design is shown. The magnified membrane region illustrates net diffusion of a compound (analyte) of interest (blue circles) into the probe, as well as the net diffusion of the calibrator (red circles), which has been added to the perfusate, from the probe to the extracellular space. Redrawn with permission from [90].

of aortic plaque material, and also leakage of air via the intravascular catheters, can occur during use. With current surgical heart assist technologies and adequate anticoagulation, the risk of clinically relevant embolization has been minimized [85,86]. It is likely that with cautious implantation and adequate anticoagulation, the risk of cerebral damage caused by PVAD systems may be comparable with conventional cardiac catheterization procedures [87].

Assessment of cerebral injury

Clinical data of cerebral damage during PVAD support have not been reported. Generally, examination of cerebral perfusion and metabolism can involve complicated and invasive procedures and may in some cases be in conflict with guidelines for accepted intervention. The experimental setting allows for controlled hemodynamic intervention, and experimental models make feasible more sophisticated monitoring of cerebral circulation, metabolism and injury. Animal models include the possibility for direct intracardiac and intravascular monitoring and sampling, and also tissue flow measured with labeled microsphere injections, which is considered a gold standard approach for the assessment of tissue perfusion. Analysis requires harvesting of tissue for photometroscopic analysis, which complicates the use of this method in human subjects [88,89].

The newly developed cerebral microdialysis represents a method for the direct assessment of cerebral metabolism and redox state and is related to cerebral perfusion and to neurological injury [90–92]. With this technique, a miniature intracerebral dialysis catheter implanted via a cranial burr hole allows for continuous sampling of intracerebral molecules (Figure 6). Intracerebral dialysate can be analyzed for metabolic markers during clinical and experimental cerebral ischemia or injury. The method has been validated clinically and experimentally and is established in clinical use for monitoring of patients with cerebral injury [93–97]. Available data include reports from cerebral trauma, intracranial hemorrhage, cardioplegia and resuscitated cardiac arrest [17,98,99]. During cerebral hypoperfusion, markers of ischemia or injury can be sampled and analyzed continuously, and changes in the metabolic status of the cerebral cortex can be detected with little delay and followed over time. It is likely that this technique will be useful in future studies of cerebral status in hemodynamically compromised patients.

Assessment of cerebral injury

Clinical data of cerebral damage during PVAD support have not been reported. Generally, examination of cerebral perfusion and metabolism can involve complicated and invasive procedures and may in some cases be in conflict with guidelines for accepted intervention. The experimental setting allows for controlled hemodynamic intervention, and experimental models make feasible more sophisticated monitoring of cerebral circulation, metabolism and injury. Animal models include the possibility for direct intracardiac and intravascular monitoring and sampling, and also tissue flow measured with labeled microsphere injections, which is considered a gold standard approach for the assessment of tissue perfusion. Analysis requires harvesting of tissue for photometroscopic analysis, which complicates the use of this method in human subjects [88,89].

The newly developed cerebral microdialysis represents a method for the direct assessment of cerebral metabolism and redox state and is related to cerebral perfusion and to neurological injury [90–92]. With this technique, a miniature intracerebral dialysis catheter implanted via a cranial burr hole allows for continuous sampling of intracerebral molecules (Figure 6). Intracerebral dialysate can be analyzed for metabolic markers during clinical and experimental cerebral ischemia or injury. The method has been validated clinically and experimentally and is established in clinical use for monitoring of patients with cerebral injury [93–97]. Available data include reports from cerebral trauma, intracranial hemorrhage, cardioplegia and resuscitated cardiac arrest [17,98,99]. During cerebral hypoperfusion, markers of ischemia or injury can be sampled and analyzed continuously, and changes in the metabolic status of the cerebral cortex can be detected with little delay and followed over time. It is likely that this technique will be useful in future studies of cerebral status in hemodynamically compromised patients.
Recently, brain-specific peptides released into the bloodstream have been demonstrated to correlate with the extent of neurological damage and with prognosis for patients with brain injury, and could be useful as an indirect measure of cerebral circulatory status [112–114]. However, current data assessing neuron-specific enolase during LVAD support without cerebral ischemia found results to be unspecific and interpretation unclear in the presence of concomitant cardiac disease [115].

Blood flow to the head can be indirectly assessed with sidestream dark-field analysis [42], which permits direct and continuous assessment of microcirculation in the tongue. The method is easy to use and attractive in clinical use but has not been validated with regards to cerebral injury or neurological injury after cerebral hypoperfusion.

Future clinical studies should be designed to assess both cerebral perfusion and injury during the acute treatment phase, and to detect and quantify neurological injury in survivors. The use of transcranial Doppler flow, infrared technology, neuropeptide markers and cerebral microdialysis may all give rapid information with regards to cerebral circulatory and metabolic state. In stabilized patients, neurological testing can be supplemented with CT, MRI and PET-scan imaging for evaluating brain injury and dysfunction [95].

### Conclusion

Recently developed PVAD technology improves hemodynamics and tissue perfusion as indicated by clinical and experimental studies, but a mortality benefit has not been found.

Experimental data suggest the Impella LP 2.5 device may be able to sustain cerebral perfusion in cardiac arrest, and that systemic circulation and cerebral perfusion can be monitored via end-tidal CO₂. Cerebral injury is a major limitation of outcomes after resuscitation and these recent findings indicate PVAD support may be of benefit in this setting.

The available data indicate a possible role for PVAD therapy for prevention of brain injury in cardiac arrest. Further studies are required to elucidate the potential of PVAD support to prevent cerebral hypoperfusion compared with conventional CPR in the clinical setting.

### Future perspective

Percutaneous ventricular assist devices represent a future potential for improving outcomes in patients with critical cerebral hypoperfusion secondary to acute heart failure or cardiac arrest. The use of Impella support during coronary revascularization in cardiac arrest may be of particular advantage as revascularization could be performed without concomitant chest compressions and without the use of vasopressor drugs. If pulse-generating rhythm is restored, the PVAD may have a beneficial effect on myocardial oxygen consumption during the recovery phase. Investigation of the effect of PVAD therapy for preventing cerebral ischemia in different clinical scenarios should be the scope of future clinical studies.

### Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancy, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

<table>
<thead>
<tr>
<th>Executive summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cerebral ischemia in cardiac collapse</strong></td>
</tr>
<tr>
<td>• Brain injury limits outcomes after successful resuscitation; novel therapeutic approaches may be warranted.</td>
</tr>
<tr>
<td><strong>Percutaneous ventricular assist device therapy in acute cardiac collapse</strong></td>
</tr>
<tr>
<td>• Allows safe and rapid hemodynamic support in cardiogenic shock and high-risk percutaneous coronary intervention, and may have the potential to improve outcomes compared with more complicated surgical devices.</td>
</tr>
<tr>
<td><strong>Cerebral blood flow with percutaneous ventricular assist devices in clinical use</strong></td>
</tr>
<tr>
<td>• There are no clinical reports on cerebrovascular complications. Percutaneous ventricular assist devices (PVADs) may improve microcirculation in the head in cardiogenic shock.</td>
</tr>
<tr>
<td><strong>Prevention of cerebral ischemia with PVADs</strong></td>
</tr>
<tr>
<td>• The Impella® LP 2.5 device can maintain cerebral perfusion at a clinically relevant level during experimental cardiac arrest. Cerebral ischemia assessed with cerebral microdialysis may be avoided during the initial 20 to 40 min of ventricular fibrillation.</td>
</tr>
<tr>
<td><strong>Conclusion</strong></td>
</tr>
<tr>
<td>• PVAD therapy may represent a promising strategy for improving outcomes after cardiac arrest and severe hemodynamic compromise.</td>
</tr>
<tr>
<td>• Adjunctive treatment, including fluid loading, may have the potential to further enhance the effect of PVADs.</td>
</tr>
<tr>
<td>• Clinical trials should be performed to further investigate the potential of PVAD therapy in preventing cerebral ischemia.</td>
</tr>
</tbody>
</table>
Clinical assessment of TandemHeart®.


Assessment of cerebral ischemia during experimental cardiac arrest with Impella support.


Role of percutaneous left ventricular assist devices in preventing cerebral ischemia


Clinical assessment of Impella® LP 2.5.


Clinical neurological outcomes post-resuscitation in ST-segment elevation myocardial infarction patients.


Role of percutaneous left ventricular assist devices in preventing cerebral ischemia


